Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.94 |
| ▸ | ESR2 | Q92731 | 8/20 | 0.62 |
| ▸ | ESR1 | P03372 | 7/20 | 0.62 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.58 |
| ▸ | HSD17B2 | P37059 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 2/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.56 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Betanaphthol SCHEMBL239472 | 0.97 | CYP1A2 (1.00) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL28781 | 0.97 | CYP1A2 (1.00) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL29658180 | 0.97 | CYP1A2 (1.00) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL11594695 | 0.97 | CYP1A2 (1.00) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL9116084 | 0.94 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL7614327 | 0.94 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL565209 | 0.94 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL11026449 | 0.94 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL14973607 | 0.94 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 | |
| Betanaphthol SCHEMBL11678336 | 0.94 | CYP1A2 (0.94) | CYP1A2ESR2ESR1HSD17B1HSD17B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220384856-A1 | MITIGATING THE ZINCATE EFFECT IN ENERGY DENSE MANGANESE DIOXIDE ELECTRODES | RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK | 2022-12-01 | — | — | US | claimed |
| US-12002951-B2 | Buffer interlayers in membraneless high voltage batteries | URBAN ELECTRIC POWER INC. (US) | 2024-06-04 | — | — | US | disclosed |
| CN-112106234-B | Method for making manganese dioxide and its polymorphs reversible | 纽约城市大学研究基金会 | 2024-03-08 | — | — | CN | disclosed |
| US-20230402593-A1 | DEVICE AND METHOD FOR UTILIZING INTERCALATION ZINC OXIDE WITH AN ELECTRODE | UNIV CITY NEW YORK RES FOUND (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230344014-A1 | METAL-FREE HIGH VOLTAGE BATTERY | URBAN ELECTRIC POWER INC. | 2023-10-26 | — | — | US | disclosed |
| WO-2023183579-A2 | ION SELECTIVE LAYERS AND APPLICATIONS THEREOF | URBAN ELECTRIC POWER INC. (US) | 2023-09-28 | — | — | WO | disclosed |
| US-20230197975-A1 | AQUEOUS HIGH VOLTAGE ZINC-ANODE BATTERY | URBAN ELECTRIC POWER INC. | 2023-06-22 | — | — | US | disclosed |
| US-20230187623-A1 | IMPROVING ZINC-MANGANESE DIOXIDE BATTERY PERFORMANCE THROUGH INTERLAYERS | URBAN ELECTRIC POWER INC. | 2023-06-15 | — | — | US | disclosed |
| EP-4136689-A1 | METAL-FREE HIGH VOLTAGE BATTERY | Urban Electric Power Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| EP-4136692-A1 | AQUEOUS HIGH VOLTAGE ZINC-ANODE BATTERY | Urban Electric Power Inc. (US) | 2023-02-22 | — | — | EP | disclosed |
| US-20060110428-A1 | Methods and devices for the treatment of ocular conditions | SURMODICS MD, LLC | 2006-05-25 | — | — | US | disclosed |
| WO-2006014484-A2 | METHODS AND DEVICES FOR THE TREATMENT OF OCULAR CONDITIONS | SURMODICS, INC. (US) | 2006-02-09 | — | — | WO | disclosed |
| US-20050002865-A1 | Diagnostic/therapeutic agents | AMERSHAM HEALTH AS (NO) | 2005-01-06 | — | — | US | disclosed |
| US-20040141922-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2004-07-22 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040141922-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CYP1A2 4874/4885ESR2 1745/4885ESR1 2252/4885 |
| US-20050002865-A1 | Diagnostic/therapeutic agents | FUS, HNRNPF, HNRNPR | CYP1A2 4806/4885ESR2 1111/4885ESR1 1133/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | CYP1A2 4880/4885ESR2 1929/4885ESR1 2385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.